Last updated on April 21, 2014 at 10:25 EDT

Dr. Yamo Deniz to Join Cytos Biotechnology’s Board of Directors

December 4, 2013

ZURICH, December 4, 2013 /PRNewswire/ –

Cytos Biotechnology Ltd (SIX:CYTN) (“Cytos” or the “Company”) today announced that Dr.
Yamo Deniz is proposed to join Cytos’ Board of Directors. Dr. Deniz played a key role in
the filing and approval of multiple drugs and in-vivo diagnostics agents in several
therapeutic areas of unmet need, including omalizumab (Xolair(R)) for the treatment of
asthma in the US and the EU. His extensive experience in the clinical development of
asthma products further strengthens Cytos’ Board of Directors.

Dr. Christian Itin, Chairman and CEO of Cytos, said: “With Dr. Yamo Deniz we are
strengthening our Board of Directors with an industry expert in allergic asthma, the key
area of focus for our lead program CYT003. His experience in developing, obtaining
approval for and commercialization of the first biological in asthma is highly relevant
for the development and positioning of CYT003. Dr. Yamo Deniz will join as an independent

About Dr. Yamo Deniz

Yamo Deniz, MD, currently serves as Chief Medical Officer, Global Head of Medical &
Pharmacovigilance at GE Healthcare Lifesciences. Prior to joining GEHC in 2010, Dr. Deniz
held numerous senior clinical and leadership positions of increasing responsibilities in
respiratory as well as inflammation groups at Genentech and Roche, respectively. Dr. Deniz
played a key role in the filing and approval of multiple drugs and in-vivo diagnostics
agents in several therapeutic areas of unmet need, including omalizumab (Xolair(R)) for
the treatment of asthma in the US and the EU. He also oversaw the lifecycle management
plans of marketed products for other indications. In addition, he led Genentech’s Peanut
Allergy program. Dr. Deniz graduated with a BA in Chemistry from the College of the Holy
Cross. After finishing his medical studies at the University of Massachusetts, Dr. Deniz
completed a pediatric residency in New York and a sub-specialty training in Pediatric
Allergy & Immunology at Duke University Medical Center in North Carolina. Prior to joining
Genentech in 2001, Dr. Deniz worked at the Karolinska Institutet Pediatric Hospital and
remains actively involved in the respiratory, allergy and immunology fields. He currently
also serves as a member of the corporate scientific advisory board of DBV Technologies.

Extraordinary Shareholders’ Meeting on December 30, 2013

In order to elect Dr. Deniz to the Board of Directors, an extraordinary shareholders’
meeting will be held on December 30, 2013. Additional agenda items at this meeting are an
increase of the authorized share capital by 2’715’946 registered shares and an increase of
the conditional share capital for financing purposes by 905’315 registered shares,
bringing both authorized and conditional share capital to 50% of the issued share capital.
In addition, the Board proposes an amendment to the resolution no. 2 of the annual general
meeting of shareholders held on June 28, 2013 (Compensation of Loss). The invitation for
the shareholders meeting will be mailed to registered shareholders within the next few

The invitation including the agenda is available for downloading at


About CytosBiotechnology Ltd

Cytos is a public biopharmaceutical company focused on the development of targeted
immuno-therapies. The Company’s lead product candidate CYT003 is a novel, first-in-class,
immune modulator in Phase 2 clinical development as a potential new treatment for asthma.

CYT003 has a novel mechanism of action that inhibits the immune response that causes
asthma, and may therefore be beneficial for the control of asthma. In a successfully
completed Phase 2a study, CYT003 was shown to maintain asthma control and lung function in
patients with persistent allergic asthma, despite withdrawal of standard therapy with
inhaled corticosteroids. CYT003 has been shown to have a good safety and tolerability
profile in more than 450 individuals receiving the active agent so far.

Cytos was founded in 1995 as a spinoff from the Swiss Federal Institute of Technology
(ETH) in Zurich. It is located in Schlieren (Zurich), Switzerland. The Company is listed
according to the Main Standard on the SIX Swiss Exchange Ltd under the symbol CYTN.


Forward Looking Statements

This media release contains certain forward-looking statements that involve risks and
uncertainties that could cause actual results to be materially different from historical
results or from any future results expressed or implied by such forward-looking
statements. You are urged to consider statements that include the words “committed”,
“could”, “will”, “plans”, “enable”, “expected”, “proposed”, “intends”, “planned,” or the
negative of those words or other similar words to be uncertain and forward-looking.
Factors that may cause actual results to differ materially from any future results
expressed or implied by any forward-looking statements include scientific, business,
economic and financial factors, including that CYT003 may not demonstrate safety or
efficacy in clinical trials, that there may be delays in development or that CYT003 may
not receive marketing approval, and that the Company relies on outside financing to meet
capital requirements, which may not be available under acceptable terms or at all. Against
the background of these uncertainties, readers should not rely on forward-looking
statements. The Company assumes no responsibility for updating forward-looking statements
or adapting them to future events or developments.

        For further information, please contact:

        Cytos Biotechnology Ltd
        Harry Welten
        Chief Financial Officer
        Tel: +41-44-733-46-46
        e-mail: harry.welten@cytos.com

        US Investor enquiries
        Susan A. Noonan
        Tel: +1-(212)-966-3650
        e-mail: susan@sanoonan.com

SOURCE Cytos Biotechnology Ltd

Source: PR Newswire